

EDITORIAL

IMPACT OF IMMUNITY IN AUTISM SPECTRUM DISORDERS

S. TETÈ¹, G. VARVARA¹, G. MURMURA¹, A. SAGGINI², G. MACCAURO³,
M. ROSATI⁴, E. CIANCHETTI⁵, D. TRIPODI¹, E. TONIATO⁶, M. FULCHERI⁷,
A. CARAFFA⁸, P. ANTINOLFI⁸, F. PANDOLFI⁹, G. POTALIVO⁸, P. CONTI⁶
and T.C. THEOHARIDES¹⁰

¹Dental School, University of Chieti-Pescara, Chieti, Italy; ²Dermatology Department, University Tor Vergata, Rome, Italy; ³Orthopedics Division, Università Cattolica, Rome, Italy; ⁴Gynecology Division, Pescara Hospital, Italy; ⁵Department of Surgery, Ortona ASL Hospital, Ortona, Italy; ⁶Immunology Division, Medical School, University of Chieti-Pescara, Italy; ⁷Psychology School, University of Chieti-Pescara, Italy; ⁸Orthopedics Division, University of Perugia, Italy; ⁹Department of Medicine, Catholic University of Rome, Rome, Italy; ¹⁰Internal Medicine and Biochemistry, Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine and Drug Discovery Laboratory, Tufts-New England Medical Center, Boston, MA, USA

Received November 30, 2012 – Accepted February 18, 2013

Autism spectrum disorders (ASDs) are childhood psychopathologies characterized by having difficulties in social interaction, verbal and non-verbal communication as well as sensor motor movements. Evidence suggests that in ASDs environmental toxicant exposure, genetic and mitochondrial dysfunction are involved associated with abnormal immune response with allergic problems and elevated serum IgE. ASDs present the major cytokine and chemokine dysfunction in CNS and is mediated by an increase of pro-inflammatory cytokine levels in the brain, such as TNF, IL-1, IFN- γ , IL-6, IL-8 and others. Mast cells, which are also implicated in ASDs, are worsened by stress and produce proinflammatory cytokines and can be stimulated by neurotensin in the brain and gut, contributing also to the inflammatory response. However, the exact etiology of ASDs remains largely unknown.

Covering the literature from 2003 to the present in PubMed, this editorial summarizes the interrelationship between immunology and autistic subjects. Autism spectrum disorders (ASD) are characterized by having difficulties in social interaction, verbal and non-verbal communication, repetitive behavior, and sensory motor movements (1-3). The prevalence of ASD is about 1% in the US and the number of children with a diagnosis of an ASD has been on the rise for over two decades.

These disorders involve hormonal perturbations in pregnancy or early childhood in the context of genetic control and have become recognized as common childhood psychopathologies. These early molecular events, at a time of rapid development, are intimately linked to concurrent development in the brain and immune system. Autism usually occurs in the first three years of childhood and in spite of increasing diagnosis in recent years, the exact etiology of autism remains largely unknown. Findings also

Key words: autism spectrum disorders, cytokines, inflammation, immunity

Mailing address: Prof. S. Tetè,
Dipartimento di Scienze Orali,
Università "G. d'Annunzio" Chieti- Pescara",
Via dei Vestini, 31
Chieti, Italy
Tel./Fax: +39 0871 3554095
e-mail: tete@unich.it

1721-727X (2013)

Copyright © by BIOLIFE, s.a.s.

This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder.

Unauthorized reproduction may result in financial and other penalties

DISCLOSURE: ALL AUTHORS REPORT NO CONFLICTS OF INTEREST RELEVANT TO THIS ARTICLE.

support the view that neuro-immune abnormalities occur in the brain of autistic patients and may contribute to the diversity of the autistic phenotypes, although several lines of research support the view that this is a result of a complex combination of neurological, environmental, immunological, and genetic factors. Most proposed perinatal factors seem to converge into the activation of the immune system, suggesting that an early inflammatory response could be a unifying factor in the etiology of autism spectrum disorders. The inflammation could be caused by a defective placenta, immature blood-brain barrier, the immune response of the mother to infection while pregnant, a premature birth, encephalitis in the child after birth, or a toxic environment. However, evidence suggests that in autism genetic, environmental toxicant exposures, oxidative stress and mitochondrial dysfunction are involved (4-7). Therefore, we are convinced that autism spectrum disorder is also associated with altered neuro-inflammatory processes and abnormal immune responses in adulthood. How these immune alterations can affect developmental programming of adult behavior or directly affect behavior later in life is unclear. Therefore the etiological base of autism is still not understood.

It has been reported that ASD children may present a type of allergic problem but in the absence of elevated serum IgE. These findings suggest non-allergic mast cell activation, probably in response to environmental and stress triggers that could contribute to inflammation.

Several authors have reported that elevated cytokines in the cerebral spinal fluid of living autistic children play an important role in the neuro-inflammatory process linked to this disease(s). Many authors reported that cytokine imbalances in autism have pathological roles and have important interaction with the nervous system, contributing to the dysfunction in autism spectrum disorders (8-12).

Although many cytokines and their receptors remain unstudied, the major cytokines interleukin-1 (IL-1)- α , IL-1- β , IL-4, IL-6, IL-10, IL-11, IL-13, IL-18, TNF- α , IL-1-RA, TGF- β , and CCL2 are all expressed in the healthy CNS (13-16). Many of these cytokines and their receptors have differential expression patterns across the CNS. Interleukin-1, Interleukin-6 (IL-1, IL-6) and tumor necrosis factor

alpha (TNF-alpha) are pro-inflammatory cytokines, which represent the key mediators of neuroimmune interactions, leading to severe neurological and mental diseases. IL-6 mRNA and its receptor (IL-6R) are developmentally regulated in the rat brain (17-19) and the adult hippocampus has the highest detectable levels of both transcripts; while IFN- γ is found at neuronal synapses (20-23) suggesting that it may act at the level of the synapse to influence brain function.

It has been reported that many cytokines, such as IL-1-beta, IL-6, IL-4, IFN- γ , and TGF-beta, are implicated in the nervous system and therefore in autism. Other authors reported that increased pro-inflammatory cytokine levels in the brain (TNF- α , IFN- γ , IL-1 β and IL-8); and NF-kappaB, may also contribute to autism spectrum disorders (24-27). In addition, other authors confirmed that several cytokines and chemokines, including IL-1 β , IL-6, IL-8 and IL-12p40, are elevated in the ASD plasma of very young children (ages 2-5 years old), and that these increases are associated with more impaired communication and aberrant behaviors (28-31).

It has been reported that mast cells express leptin and leptin receptors, a finding implicating paracrine or autocrine immunomodulatory effects of leptin on mast cells (32-35). Leptin may play a role in ASD. In fact, leptin is higher in obese subjects (36-42) and elevated plasma leptin levels during pregnancy are indicative of placental dysfunction (43-46) and plasma levels of leptin are significantly higher in patients with autistic disorder.

Stress also may have a role in this disease(s). Acute stress leads to high serum IL-6 that is mast cell-dependent (47-49). Mast cells have been implicated in inflammatory conditions that are worsened by stress (50-52). Mast cell-derived cytokines, such as IL-6, can increase blood-brain-barrier (BBB) permeability (47, 53-56). Corticotropin-releasing hormone (CRH) may have an immunomodulatory role and has been associated with intestinal inflammation. In addition, CRH can also be secreted from immune cells (57-60), mast cells (61-63), skin (64-69) and post-ganglionic nerve endings (70-72), leading to pro-inflammatory effects (73-75). When mast cells are activated with CRH they release several pro-inflammatory cytokines (76-78). Patients with stress, result in secretion

of CRH from the hypothalamus and regulates the hypothalamic-pituitary-adrenal (HPA) axis (79-81). Increased plasma levels of CRH have been linked to preterm labor (82-85) and in mothers with anxiety during that period of pregnancy (86). A number of cytokines, including IL-1 and IL-6, can trigger secretion of CRH *in vitro* (87-89). Moreover, CRH stimulates IL-6 release from human peripheral blood mononuclear cells that infiltrate the fetal membranes and the placenta during intrauterine infection (90-91).

Other cytokines may also be implicated in ASD. For instance, TNF increases about 50-fold in the cerebrospinal fluid and IL-6 gene expression also increases in the brain of ADS patients. Since mast cells are surely involved in this disease, macrophage chemoattractant-protein-1 (MCP-1), a potent chemoattractant for mast cells, is also important. Acting on mast cells, TGF- β 1 along with IL-9 may also have a role in worsening ASD symptoms. Recently, it has been reported that IL-9 induces mast cell release of vascular endothelial growth factor (VEGF) (92-94) which also inhibits gut mast cell function (95-96). In addition to cytokines, essential components of the complement cascade, including C1q and C3, are also expressed in the CNS.

Neurotensin (NT) is a brain and gut peptide that contributes to gut inflammation due to acute stress (97-98). This is an important molecule, augmented and secreted in serum of children with autism (99-100), which can stimulate mast cell and mediate ASD. A common link among the neurobehavioral disorders associated with intrauterine inflammation appears to be the evidence for immune dysregulation in the developing brain. Other immune parameters, including maternal infection and dysregulated cytokine signaling, have been found to be associated with ASD. However, the role of the cytokines in the pathogenesis of ADS remain to be determined.

While detailed pathogenic mechanisms remain unclear, the hypothesis that some cases of ASD may be influenced, or even caused, by maternal fetal brain-reactive antibodies or other *in utero* immune-related exposures is an important area of investigation.

It has been observed that extremely high gamma-aminobutyric acid (GABA) levels in the urine and blood and high plasma ammonia (NH₃) were found in a child with autism. This concept is very important

since GABA is considered a major inhibitory neurotransmitter of the mammalian brain and in particular the corpus callosum, located in the center of the brain, involved in intelligence, language and speech. Moreover, Cohen has also demonstrated that elevated levels of NH₃ in the plasma result in a decrease in the efficiency of the enzyme GABA-transaminase, which is responsible for the catabolism of GABA.

Articles showing peripheral immune abnormalities support immune hypotheses, but until recently there have been no immune findings. However, several immune abnormalities have been noted in autistic subjects. For example, the question of a connection between vaccination and autism is surrounded by controversy. In addition, several studies showing elevated brain specific antibodies in autism support an autoimmune mechanism. However, recently it has been reported that vaccines as well as autoimmunity do not seem to be the cause of autism. In addition, an involvement of gastrointestinal pathophysiology in autism has been reported; however, other studies also reported no association between autism and gastrointestinal diseases.

Another important parameter in autism is the augmented whole blood serotonin (5-HT) levels found in about 1/3 of cases. Serotonin and other biogenic amines have been shown to facilitate formation and maintenance of synapses in the central nervous system. Neurons in the cerebral cortex express serotonin 5-HT_{2A} receptor which has been shown to mediate the function of serotonin. Immune dysfunctions in autism are related to hyperserotoninemia, autoantibodies to 5-HT receptors, and 5-HT's role in autoimmunity.

C4 component of a classical complement pathway has been associated with several diseases. C4 has been identified in developing brain neurons. C4 allotype deficiency may be important in disease pathogenesis and is related to C4B deficiency and autoimmune-associated diseases, such as autism.

Interleukins (IL) are inflammatory proteins that modulate the immune system. Inflammation leads to the tissue damage and release of pro-inflammatory cytokines, which augment the above process. The tissue damage causes exposure of nerve endings, which can lead to the activation of axon reflexes. Environmental factors that may trigger the expression

and secretion of cytokines in inflammatory diseases include: alcohol, cigarette smoking, pollution, infection and possibly stress.

These factors, may initiate the process of immune activation but the subsequent release of cytokines is the damaging factor associated with autism. In fact, our hypothesis is related to the neuroglia activation by cytokines leading to neuro-inflammation. Inflammatory mediators in autism usually involve activation of astrocytes and microglial cells. In addition, pro-inflammatory chemokines such as MCP-1 and modulatory cytokine, such as TGF-beta-1, are consistently elevated in autistic brains. However, the role of the immune system in the development of autism is controversial.

We recently reported a discovery which may have uncovered an important clue to causes of the development of Autism. A strong connection is believed to be the disease mastocytosis in which the skin and the intestines contain more mast cells than average. These mast cells are very sensitive to various allergenic triggers. In the past, mast cells were thought to be reactive in allergic conditions such as pollens and various animal hairs. We were the first to show in our report published in the journal, "Trends in Pharmacological Sciences", that stress and viruses can also be accomplices in the activation of mast cells. In our findings, only about 10-12% of patients had allergic reactions. Thus, our goal was to determine what the mast cell does in people who do not have allergies.

We learned that many mastocytosis patients had at least one family member with both mastocytosis and autism. We were excited to have found a relationship between autism and mastocytosis. This discovery would allow researchers to study the role of mast cells and provide insight into the connection with autism. Researchers are trying to understand the role of the mast cell in the brain because they are aware of patients with mast cell disorders who also manifest central nervous system symptoms.

We are in the process of requesting funding for additional studies investigating this relationship between mast cell and autism.

We suggest that the previous thought that was connected to "leaky gut" theory in children does not stand, as several studies of this nature have been disproved. Instead, we are searching for other causes

which stimulate mast cells both in the intestines and the brain of young children ages 1-4. We feel that some food, stress or viruses could activate mast cells in the intestine. It is believed that these would cause the cells to release cytokines which disrupt the lining of the intestines and of the brain. When the protective layer of the brain is disrupted, noxious substances are allowed entry. These substances could cause an inflammation of the brain which is believed to be a cause or a contributor to autism.

Together, these reports suggest that autism may in fact be a systemic disorder with connections to abnormal immune responses. Therefore, we believe that a better understanding of this mechanism/s in the pathogenesis of autism and the involvement of the immune response, may have important clinical and therapeutic implications and may represent novel targets for treatment.

REFERENCES

1. Rapin I. Autism. *N Engl J Med* 1997; 337:97-104.
2. di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti C, Acciavatti T, Cornelio M, Martinotti G. Major depressive disorder, anhedonia, and agomelatine: an open-label study. *J Biol Regul Homeost Agents* 2011; 25:109-14.
3. Orciani M, Morabito C, Emanuelli M, Guarnieri S, Sartini D, Giannubilo SR, Di Primio R, Tranquilli AL, Mariggiò MA. Neurogenic potential of mesenchymal-like stem cells from human amniotic fluid: the influence of extracellular growth factors. *J Biol Regul Homeost Agents* 2011; 25:115-30.
4. Bekenstein U, Soreq H. Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: From structural insights to post-transcriptional regulatory roles. *Mol Cell Neurosci* 2012; S1044-7431.
5. Zizzi A, Aspriello SD, Rubini C, Goteri G. Peri-implant diseases and host inflammatory response involving mast cells: a review. *Int J Immunopathol Pharmacol* 2011; 24:557-66.
6. Graham MR, Myers T, Evans P, Davies B, Cooper SM, Bhattacharya K, Grace FM, Baker JS. Direct hits to the head during amateur boxing is associated with a rise in serum biomarkers for brain injury. *Int J*

- Immunopathol Pharmacol 2011; 24:119-25.
7. Chiricozzi A, Zhang S, Dattola A, Cannizzaro MV, Gabellini M, Chimenti S, Nisticò SP. New insights into the pathogenesis of cutaneous autoimmune disorders. *J Biol Regul Homeost Agents* 2012; 26:165-70.
 8. Wang J, Ke T, Zhang X, Chen Y, Liu M, Chen J, Luo W. Effects of acetazolamide on cognitive performance during high-altitude exposure. *Neurotoxicol Teratol* 2012; doi:pii: S0892-0362(12)00179-1.
 9. Marotta F, Chui DH, Yadav H, Lorenzetti A, Celep G, Jain S, Bomba A, Polimeni A, Zhong K, Allegri F. Effective properties of a sturgeon-based bioactive compound on stress-induced hippocampal degeneration and on *in vitro* neurogenesis. *J Biol Regul Homeost Agents* 2012; 26:327-35.
 10. Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis. *Int J Immunopathol Pharmacol* 2011; 24:261-4.
 11. Carlesimo M, Narcisi A, Orsini D, Abruzzese C, Di Russo PP, La Verde G, Cox MC. Eosinophilic dermatosis associated with haematological malignancies: a report of two cases. *Eur J Inflamm* 2012; 10:247-50.
 12. Dianzani C, Pizzuti A, Gaspardini F, Bernardini L, Rizzo B, Degener AM. Ulerythema ophryogenes, a rare and often misdiagnosed syndrome: analysis of an idiopathic case. *Int J Immunopathol Pharmacol* 2011; 24:523-7.
 13. Bauer M, Szulc J, Meyer M, Jensen CH, Terki TA, Meixner A, Kinkl N, Gasser T, Aebischer P, Ueffing M. Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons. *J Neurochem* 2008; 104:1101-15.
 14. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Putini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor- α blocking agents in rheumatoid arthritis. *Int J Immunopathol Pharmacol* 2011; 24(1):269-74.
 15. Giganti MG, Minella D, Testa B, Zenobi R, Biancolella M, Isidori AM, Caprio M, Novelli G, Fabbri A. A pilot study on the transcriptional response of androgen- and insulin-related genes in peripheral blood mononuclear cells induced by testosterone administration in hypogonadal men. *J Biol Regul Homeost Agents* 2011; 25:291-294.
 16. Hatzistilianou M, Antoniadis D, Zournatzi V, Pappa S, Antoniadis M, Koiou K, Frydas I, Tzafetas J. Isoenzymes of adenosine deaminase and metalloproteinases as biomarkers in *in vitro* fertilization and embryo transfer. *Int J Immunopathol Pharmacol* 2011; 24:25-31.
 17. Gadiant RA, Otten U. Identification of interleukin-6 (IL-6)-expressing neurons in the cerebellum and hippocampus of normal adult rats. *Neurosci Lett* 1994; 182:243-6.
 18. Quintero P, González-Muniesa P, Martínez JA. Influence of different oxygen supply on metabolic markers and gene response in murine adipocytes. *J Biol Regul Homeost Agents* 2012; 26:379-388.
 19. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Bartels H, Bartels PH, Alberts DS, Montironi R. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. *Int J Immunopathol Pharmacol* 2011; 24:489-97.
 20. Vikman K, Robertson B, Grant G, Liljeborg A, Kristensson K. Interferon-gamma receptors are expressed at synapses in the rat superficial dorsal horn and lateral spinal nucleus. *J Neurocytol* 1998; 27:749-59.
 21. Mazzocchi G, Vendemiale G, De Cata A, Tarquini R. Change of $\gamma\delta$ TCR-expressing T cells in healthy aging. *Int J Immunopathol Pharmacol* 2011; 24(1):201-9.
 22. Catanzaro R, Marotta F, Jain S, Rastmanesh R, Allegri F, Celep G, Lorenzetti A, Polimeni A, Yadav H. Beneficial effect of a sturgeon-based bioactive compound on gene expression of tumor necrosis factor- α , matrix metalloproteinases and type-10 collagen in human chondrocytes. *J Biol Regul Homeost Agents* 2012; 26:337-45.
 23. Ricci G, Piccinno V, Giannetti A, Miniaci A, Specchia F, Masi M. Evolution of hypogammaglobulinemia in premature and full-term infants. *Int J Immunopathol Pharmacol* 2011; 24:721-26.
 24. Kern JK, Geier DA, Audhya T, King PG, Sykes LK, Geier MR. Evidence of parallels between mercury

- intoxication and the brain pathology in autism. *Acta Neurobiol Exp (Wars)* 2012; 72:113-53.
25. Wang JC, Sonnylal S, Arnett FC, De Crombrughe B, Zhou X. Attenuation of expression of extracellular matrix genes with siRNAs to Sparc and Ctgf in skin fibroblasts of CTGF transgenic mice. *Int J Immunopathol Pharmacol* 2011; 24:595-601.
 26. Chiricozzi A, Zhang S, Dattola A, Gabellini M, Chimenti S, Nisticò SP. Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. *J Biol Regul Homeost Agents* 2012; 26:313-18.
 27. Vignini A, Sartini D, Morganti S, Nanetti L, Luzzi S, Provinciali L, Mazzanti L, Emanuelli M. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. *Int J Immunopathol Pharmacol* 2011; 24:529-34.
 28. Patterson PH. Maternal infection and immune involvement in autism. *Trends Mol Med* 2011; 17:389-94.
 29. di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti C, Acciavatti T, Cornelio M, Martinotti G. Major depressive disorder, anhedonia, and agomelatine: an open-label study. *J Biol Regul Homeost Agents* 2011; 25:109-14.
 30. Cazzato IA, Vadrucchi E, Cammarota G, Minelli M, Gasbarrini A. Lactose intolerance in systemic nickel allergy syndrome. *Int J Immunopathol Pharmacol* 2011; 24:535-37.
 31. Saggini A, Saraceno R, Chimenti S. Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: more than a coincidental occurrence? *Int J Immunopathol Pharmacol* 2011; 24:509-15.
 32. Taildeman J, Perez-Novo CA, Rottiers I, et al. Human mast cells express leptin and leptin receptors. *Histochem Cell Biol* 2009; 131:703-11.
 33. Iezzi M, Quaglino E, Cappello P, Toto V, Sabatini F, Curcio C, Garotta G, Musiani P, Cavallo F. HCG hastens both the development of mammary carcinoma and the metastatization of HCG/LH and ERBB-2 receptor-positive cells in mice. *Int J Immunopathol Pharmacol* 2011; 24:621-30.
 34. Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. *J Biol Regul Homeost Agents* 2012; 26:347-56.
 35. Zhang J, Zhu J-S, Zhou Z, Chen W-X, Chen N-W. Therapeutic effects of ethyl pyruvate on tumor growth and metastasis in a severe combined immunodeficiency mouse orthotopic implantation model. *Eur J Inflamm* 2012; 10:25-32.
 36. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 1996; 334:292-95.
 37. Park JA, Pak JJ, Kim J, Lee EY, Lee YJ, Song YW, Lee EB. Adenosine A2A receptor polymorphisms in Korean patients with systemic sclerosis. *Int J Immunopathol Pharmacol* 2011; 24:505-8.
 38. Prus E, Fibach E. The antioxidant effect of fermented papaya preparation involves iron chelation. *J Biol Regul Homeost Agents* 2012; 26:203-210.
 39. Schumann J, Müller U, Blessing M. TGF- β signaling in T cells is not essential for Th17 cell development in the mouse. *J Biol Regul Homeost Agents* 2012; 26:357-66.
 40. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. *Front Neuroendocrinol* 2010; 31:377-93.
 41. Rivetti S, Lauriola M, Voltattorni M, et al. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant. *Int J Immunopathol Pharmacol* 2011; 24:639-49.
 42. Eusebio M, Kraszula L, Kupczyk M, Kuna P, Pietruczuk M. Low frequency of CD8+CD25+FOXP3BRIGHT T cells and FOXP3 mRNA expression in the peripheral blood of allergic asthma patients. *J Biol Regul Homeost Agents* 2012; 26:211-20.
 43. Hauguel-de MS, Lepercq J, Catalano P. The known and unknown of leptin in pregnancy. *Am J Obstet Gynecol* 2006; 194:1537-45.
 44. Li XF, Guo YJ, Wang ML, Zhang DM, Li YH, Wang YF, Tao JY, Zhang SL, Dong JH, Li LL, Zhao L. Inducing-apoptotic activity of the ethanol extract of *Duchesnea indica* Focke on treatment of herpes simplex encephalitis. *Int J Immunopathol Pharmacol* 2011; 24:631-8.
 45. Battelli MG, Ravaioli M, Musiani S, Scicchitano

- V, Grazi GL, Bolognesi A. Increased serum level of xanthine oxidoreductase in liver transplanted patients. *J Biol Regul Homeost Agents* 2011; 25:77-84.
46. Carlesimo M, Abruzzese C, Cortesi G, Ciccone AM, Poggi C, Lombardi M, Moschetti A, La Verde G, Mari E. Pseudoxanthoma elasticum and light-chain amyloidosis. *Eur J Inflamm* 2012; 10:535-537.
47. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* 2007; 12:1615-28.
48. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T. Decreased mRNA expression of two FOXP3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. *Int J Immunopathol Pharmacol* 2011; 24:7-14.
49. Caimmi S, Marseglia A, Caimmi D, Marseglia GL. Friday asthma crisis in the daughter of two bakers. *Int J Immunopathol Pharmacol* 2011; 24:517-8.
50. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 2004; 146:1-12.
51. Orciani M, Morabito C, Emanuelli M, Guarnieri S, Sartini D, Giannubilo SR, Di Primio R, Tranquilli AL, Mariggiò MA. Neurogenic potential of mesenchymal-like stem cells from human amniotic fluid: the influence of extracellular growth factors. *J Biol Regul Homeost Agents* 2011; 25:115-30.
52. Pizzicannella J, Rabozzi R, Trubiani O, Di Giammarco G. Histidine-tryptophan-ketoglutarate solution helps to preserve endothelial integrity of saphenous vein: an immunohistochemical and ultrastructural analysis. *J Biol Regul Homeost Agents* 2011; 25:93-99.
53. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. *Cell Mol Neurobiol* 2000; 20:131-47.
54. Garzaro M, Raimondo L, Pecorari G, Sensini M, Riva G, Palmo A, Giordano C. Digestibility, palatability and emotional status after ingestion of an iced dessert: analysis of subjective responses in 100 healthy volunteers. *J Biol Regul Homeost Agents* 2011; 25:101-7.
55. Kauffman MA, Sterin-Prync A, Papouchado M, et al. Immunogenicity of an interferon-beta1a product. *Int J Immunopathol Pharmacol* 2011; 24:499-504.
56. Naruishi K, Omori K, Maeda H, et al. Immune responses to *Porphyromonas gingivalis* infection suppress systemic inflammatory response in experimental murine model. *J Biol Regul Homeost Agents* 2011; 25:195-202.
57. Karalis K, Louis JM, Bae D, Hilderbrand H, Majzoub JA. CRH and the immune system. *J Neuroimmunol* 1997; 72:131-36.
58. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. *J Biol Regul Homeost Agents* 2011; 25:285-89.
59. Tarakanov I, Tikhomirova L, Tarasova N, Safonov V, Bialkowska M, Pokorski M. GABA representation in hypoxia sensing: a ventilatory study in the rat. *J Biol Regul Homeost Agents* 2011; 25:169-175.
60. Brunetti L, Recinella L, Di Nisio C, Chiavaroli A, Leone S, Ferrante C, Orlando G, Vacca M. Effects of visfatin/PBEF/NAMPT on feeding behaviour and hypothalamic neuromodulators in the rat. *J Biol Regul Homeost Agents* 2012; 26:295-302.
61. Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 2004; 145:43-48.
62. Galliera E, De Girolamo L, Randelli P, et al. High articular levels of the angiogenetic factors VEGF and VEGF-receptor 2 as tissue healing biomarkers after single bundle anterior cruciate ligament reconstruction. *J Biol Regul Homeost Agents* 2011; 25:85-91.
63. Almerigogna F, Fassio F, Giudizi MG, Biagiotti R, Manuelli C, Chiappini E, Galli L, Romagnani S, de Martino M. Natural killer cell deficiencies in a consecutive series of children with herpetic encephalitis. *Int J Immunopathol Pharmacol* 2011; 24:231-8.
64. Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. *FASEB J* 2001; 15:1678-93.
65. Pantalone A, Abate M, D'Ovidio C, Carnevale A, Salini V. Diagnostic failure of ciprofloxacin-induced

- spontaneous bilateral Achilles tendon rupture: case-report and medical-legal considerations. *Int J Immunopathol Pharmacol* 2011; 24:519-22.
66. Prada J, Shalapour S, Pfau M, Henze G, Seeger K. Antiproliferative properties of the serotonin receptor antagonist ondansetron correlate with increased nitric oxides release and inducible nitric oxide synthase activity in the acute lymphoblastic leukemia cell line REH. *Eur J Inflamm* 2012; 10:527-530.
 67. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, Tobin DJ. Corticotropin releasing hormone and the skin. *Front Biosci* 2006; 11:2230-48.
 68. Marotta F, Naito Y, Padriani F, et al. Redox balance signalling in occupational stress: modification by nutraceutical intervention. *J Biol Regul Homeost Agents* 2011; 25:221-29.
 69. Caporale CM, Notturmo F, Pace M, Aureli A, Di Tommaso V, De Luca G, Farina D, Giovannini A, Uncini A. CD1A and CD1E gene polymorphisms are associated with susceptibility to multiple sclerosis. *Int J Immunopathol Pharmacol* 2011; 24:175-83.
 70. Skofitsch G, Zamir N, Helke CJ, Savitt JM, Jacobowitz DM. Corticotropin-releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides. *Peptides* 1985; 6:307-18.
 71. Devirgiliis V, Panasiti V, Fioriti D, et al. Antibacterial activity of methyl aminolevulinate photodynamic therapy in the treatment of a cutaneous ulcer. *Int J Immunopathol Pharmacol* 2011; 24:793-5.
 72. Aguerri M, Calzada D, Martín E, et al. FOXP3 and TGF- β : differential regulatory molecules between sensitization and tolerance to olive pollen. *Eur J Inflamm* 2012; 10:193-202.
 73. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin-releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders. *Brain Behav Immunity* 1999; 13:225-239.
 74. Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. *Int J Immunopathol Pharmacol* 2011; 24:727-33.
 75. Marotta F, Naito Y, Jain S, Lorenzetti A, Soresi V, Kumari A, Carrera Bastos P, Tomella C, Yadav H. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An *in-vivo* placebo-controlled, cross-over clinical study in different age groups of healthy subjects. *J Biol Regul Homeost Agents* 2012; 26:285-94.
 76. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. *Endocrinology* 1998; 139:403-13.
 77. Mazzocchi G, Giuliani F, Sothorn RB. A method to evaluate dynamics and periodicity of hormone secretion. *J Biol Regul Homeost Agents* 2011; 25:231-238.
 78. Pizzi M, Ludwig K, Palazzolo G, Busatto G, Rettore C, Altavilla G. Cervical follicular dendritic cell sarcoma: a case report and review of the literature. *Int J Immunopathol Pharmacol* 2011; 24:539-44.
 79. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* 2007; 12:1615-1628.
 80. Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum Interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. *Int J Immunopathol Pharmacol* 2011; 24:15-23.
 81. Sedriep S, Xia X, Marotta F, et al. Beneficial nutraceutical modulation of cerebral erythropoietin expression and oxidative stress: an experimental study. *J Biol Regul Homeost Agents* 2011; 25:187-194.
 82. Makrigiannakis A, Semmler M, Briesse V, Eckerle H, Minas V, Mylonas I, Friese K, Jeschke U. Maternal serum corticotropin-releasing hormone and ACTH levels as predictive markers of premature labor. *Int J Gynaecol Obstet* 2007; 97:115-19.
 83. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Di Primio R, Bono A, Montironi R. Immunohistochemical expression and localization of somatostatin receptors in normal prostate, high grade prostatic intraepithelial neoplasia and prostate cancer

- and its many faces. *J Biol Regul Homeost Agents* 2012; 26:181-92.
84. Petraglia F, Garuti GC, De RB, Angioni S, Genazzani AR, Bilezikjian LM. Mechanism of action of interleukin-1 beta in increasing corticotropin-releasing factor and adrenocorticotropin hormone release from cultured human placental cells. *Am J Obstet Gynecol* 1990; 163:1307-12.
85. Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma. *J Biol Regul Homeost Agents* 2011; 25:177-186.
86. Angioni S, Petraglia F, Gallinelli A, Cossarizza A, Franceschi C, Muscettola M, Genazzani AD, Surico N, Genazzani AR. Corticotropin-releasing hormone modulates cytokines release in cultured human peripheral blood mononuclear cells. *Life Sci* 1993; 53:1735-1742.
87. Mancuso RA, Schetter CD, Rini CM, Roesch SC, Hobel CJ. Maternal prenatal anxiety and corticotropin-releasing hormone associated with timing of delivery. *Psychosom Med* 2004; 66:762-69.
88. Armogida M, Spalloni A, Amantea D, Nutini M, Petrelli F, Longone P, Bagetta G, Nisticò R, Mercuri NB. The protective role of catalase against cerebral ischemia *in vitro* and *in vivo*. *Int J Immunopathol Pharmacol* 2011; 24:735-47.
89. Cianci R, Pagliari D, Landolfi R, Frosali S, Colagiovanni A, Cammarota G, Pandolfi F. New insights on the role of T cells in the pathogenesis of celiac disease. *J Biol Regul Homeost Agents* 2012; 26:171-79.
90. Carraway R, Cochrane DE, Lansman JB, Leeman SE, Paterson BM, Welch HJ. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. *J Physiol* 1982; 323:403-14.
91. Ciprandi G, De Amici M, Marseglia GL. Serum IL-9 levels and sublingual immunotherapy: preliminary report. *J Biol Regul Homeost Agents* 2011; 25:295-97.
92. Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Vasiadi M, Therianou A, Theoharides TC. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. *PLoS One* 2012; 7(3):e33271.
93. Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences. *Int J Immunopathol Pharmacol* 2011; 24:673-81.
94. Angelini A, Centurione L, Sancilio SA, Castellani ML, Conti P, Di Ilio C, Porreca E, Cuccurullo F, Di Pietro R. The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines. *J Biol Regul Homeost Agents* 2011; 25:203-211.
95. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Court, Altaye M, Wills-Karp M. Elevated cytokine levels in children with autism spectrum disorder. *J Neuroimmunol* 2006; 172:198-205.
96. El-Hashim AZ, Renno WM, Abduo HT, Jaffal SM, Akhtar S, Benter IF. Effect of inhibition of the ubiquitin-proteasome-system and I κ B kinase on airway inflammation and hyperresponsiveness in a murine model of asthma. *Int J Immunopathol Pharmacol* 2011; 24:33-42.
97. Castagliuolo I, Leeman SE, Bartolac-Suki E, Nikulasson S, Qiu B, Carraway RE, Pothoulakis C. A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats. *Proc Natl Acad Sci USA* 1996; 93:12611-15.
98. Lin WY, Wu BT, Lee CC, Sheu JJ, Liu SH, Wang WF, Tsai CH, Liu HP, Tsai FJ. Association analysis of dopaminergic gene variants (Comt, Drd4 And Dat1) with Alzheimer's disease. *J Biol Regul Homeost Agents* 2012; 26:401-10.
99. Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A, Lykouras L, Kalogeromitros D, Theoharides T. Neurotensin is increased in serum of young children with autistic disorder. *J Neuroinflammation* 2010; 7:48-54.
100. Carraway R, Cochrane DE, Lansman JB, Leeman SE, Paterson BM, Welch HJ. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. *J Physiol* 1982; 323:403-14.